Evaluation of the Safety, Systemic Pharmacokinetics, and Tolerability of Single and Repeat Ocular Installations

This will be a single-center, single-arm, open label PK clinical study of loteprednol
etabonate (LE) ophthalmic gel, 0.38% conducted at one clinical center in the United States
(US), with the goal of enrolling approximately 15 healthy normal subjects in the treatment
period

Inclusion Criteria:

1. Are able to read, understand and provide written informed consent on an Informed
Consent Form (ICF) approved by the Institutional Review Board (IRB)/Independent
Ethics Committee (IEC).

2. Be a non-smoking male or female at least 18 years of age on the date the ICF is
signed and with the capacity to provide voluntary informed consent.

3. Be in general good health and free of any concomitant conditions or treatment that
could interfere with study conduct, influence the interpretation of study
observations/results, or place the subject at increased risk during the study.

4. Be willing/able to return for all required study visits and follow instructions from
the study Investigator and his/her staff.

5. Are able to self-administer eye drops or have a clinical staff member deliver the
single dose of investigational product (IP) on specified study days.

Exclusion Criteria:

1. Have a history/presence of chronic generalized systemic disease that the Investigator
feels might increase the risk to the subject, confound the result(s) of the study, or
preclude study treatment or follow-up.

2. Have any current disease or medical condition that requires medicinal therapy.

3. Have a history of drug or alcohol abuse in the last 6 months.

4. Have a positive urine screen for alcohol, amphetamines, barbiturates,
benzodiazepines, cocaine (or cocaine metabolite), cannabinoids, methadone,
methamphetamine, opiates and/or phencyclidine.

5. Are known to have a prior positive blood screen for hepatitis B surface antigen,
hepatitis C antibody, or human immunodeficiency virus types 1 and 2.